05:11 AM EDT, 09/30/2026 (MT Newswires) -- Ondine Biomedical (OBI.L) opted to use a capital access window, involving a voluntary trading pause, for its proposed equity capital raise, according to a Wednesday filing. Proceeds from the proposed fundraise would support the publication of the full Lantern trial analyses and advance US Food and Drug Administration talks for its planned new drug application submission in mid-2027, as well as commercial pilots and further sales and marketing investment for Steriwave. The life sciences company's shares entered a voluntary trading pause on AIM Wednesday until the fundraise results are announced. Ondine also plans to launch a retail offer on the same terms.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.